

1/41

(B) EFFECT OF HEPARIN ON THE AFFINITY OF  $\alpha$ -THROMBIN FOR FIBRIN

HEPARIN ( $\mu$ M)	Kd ( $\mu$ M)
0	3.22
0.1	0.25
0.25	0.15
1	0.79
20	4.26






Fig. 1


2/41

*Fig. 2*

3/41


*Fig. 3*



4/41



*Fig. 4*

5/41

*Fig. 5*

*Fig. 6A**Fig. 6B*

204220 "SEE FOOT"






Fig. 7

8/41

*Fig. 8*



9/41

*Fig. 9*

10/41




*Fig. 10*

Fig. 11



11/41

fig. 12





12/41

10019325.022702

10/019325


13/41

*Fig. 13*

14/41

	LMWH	V21		
0	21	21	0	0
0.5	24.7	23.1	12.4	1.12
1	24.3	30.7	2.37	10.1
1.5	39.4	52.1	2.98	2.31


Comparative effects of V21 and LMWH on APTT

*Fig. 14*

15/41


LMWH	V21	lmwhse	V21 se	
0	0	0	0	0
0.5	1.1	0.8	0.19	0.32
1	2.8	1.5	0.91	0.32
1.5	2.6	2.8	0.06	0.36

Comparative effects of LMWH and V21 on the anti-Xa level

*Fig. 15*

16/41

# Schematic Diagram of the Procedure




*Fig. 16*



17/41

Fig. 17

# Modified Wessler Model ( V-21) Clot Weight (%)




Treatment Groups

18/41

	LMWH	V21		
0	37.8	37.8	3.7	3.7
0.5	9.6	18	4.7	6.1
1	7.5	5.6	2.1	2.6
1.5	9.1	1.7	8.2	0.6

Comparison of LMWH and V21:Prophylaxis model

*Fig. 18*

19/41

Comparison of LMWH and V21:Prophylaxis model





Fig. 19

20/41

Fig. 20


Modified Wessler Model ( V-21) Clot Radioactivity (%)



21/41

	LMWH	V21	se	se	
0	30	30	8	8	
0.5	12	18	3.8	7.8	
1	11	5	1.7	2.1	
1.5	4.5	1.6	4.2	0.7	


Comparison of LMWH and V21: Prophylaxis Model

*Fig. 21*

22/41

Fig. 22

Comparison of LMWH and V21: Prophylaxis Model



23/41

20/2220" SEE FOOT

Comparison of LMWH and V21 in Treatment Model





Fig. 23

24/41

	LMWH	V21		
0	242	242	104	104
1	155	137	37	30
3	129	21	52	31

Comparison of LMWH and V21 in Treatment Model

*Fig. 24*



25/41

LMWH and V21 on Thrombus Accretion





fig. 25

26/41

	LMWH	V21		
0	282	282	111	111
1	202	174	37	29
3	174	57	51	20


LMWH and V21 on Thrombus Accretion

*Fig. 26*

27/41

20220" SEEF

V21 Treatment of DVT in Chronic Rabbit Model Clot Accretion



28/41

202220 "SECRET"

V21 Treatment of DVT in Chronic Rabbit Model % Change in Clot Weight






Fig. 28

29/41

*Fig. 29*

30/41





Fig. 30

31/41








Fig. 31

32/41


*Fig. 32*




33/41

*Fig. 33*

34/41

*Fig. 34*

35/41

*Fig. 35*

36/41





Fig. 36

37/41

Fig. 37

204220" SEEF00T



38/41

20/220" SEEF00T




fig. 38

39/41

202220 5261007





fig. 39

40/41

*Fig. 40*

204220" 52651001





41/41




fig. 41